Effectiveness of aprepitant in post‐acute COVID19 syndrome

Abstract

Abstract This is the first case of a patient taking aprepitant for a post‐acute COVID‐19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.

Keywords

• aprepitant
• post‐acute
• COVID19
• SARS‐CoV‐2